Prestige Consumer Healthcare Inc.
PBHPrestige Consumer Healthcare Inc. is a consumer health company specializing in over-the-counter healthcare products, including pain relief, digestive health, and personal care items. It develops, manufactures, and markets a diverse portfolio of well-known brands, primarily serving North American and international markets. The company focuses on providing trusted, everyday healthcare solutions to consumers.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 15, 2014 | $0.31 | 2013-12-27 | 2013-12-31 |
Dividends Summary
- Consistent Payer: Prestige Consumer Healthcare Inc. has rewarded shareholders with 1 dividend payments over the past 0 years.
- Total Returned Value: Investors who held PBH shares during this period received a total of $0.31 per share in dividend income.
- Latest Payout: The most recent dividend of $0.31/share was paid 4391 days ago, on January 15, 2014.
Company News
Prestige Consumer Healthcare will release its fiscal 2026 second quarter and first half earnings on November 6, 2025, before market opening, with a conference call at 8:30 a.m. ET to discuss results.
Prestige Consumer Healthcare will present at the Barclays Global Consumer Staples Conference, offering a live webcast of the event for investors and interested parties.
Prestige Consumer Healthcare Inc. announced that it will participate in a fireside chat at the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference virtually on June 11, 2025. The company reported record fiscal 2025 revenue and earnings, with organic revenue growth of 7.9% in Q4 and 1.2% in fiscal 2025.
Prestige Consumer Healthcare reported strong Q4 and fiscal 2025 results, with record revenues, organic growth, and improved profitability. The company provided an initial outlook for fiscal 2026, anticipating continued growth and earnings expansion.
Prestige Consumer Healthcare Inc. reported strong third quarter results, with record quarterly sales and earnings per share. The company's International OTC segment saw continued growth, while the Cough & Cold category declined. Prestige raised its full-year fiscal 2025 earnings outlook, citing robust free cash flow and reduced leverage.
